306 results about "Lungs tissues" patented technology

Devices and methods are provided for assessing the condition of tissue, in particular to diagnose the location and stage of diseases such as emphysema. In one device or method according to the invention, sound is introduced into lung tissue. A portion of the sound is detected after it has passed through a portion of the lung. A sound-propagation parameter is determined by comparing a property of the introduced sound and a property of the detected sound. A region of examination of the tissue is identified, based in part on either a property of the component that introduces the sound or a property of the component that detects the sound. The condition of the tissue is assessed in the region of examination, based in part on the sound-propagation parameter.

A method for studying scaffold-based tissue engineering approaches in combination with the use of progenitor or stem cells to generate new lung tissue in an in vitro system. The engineered tissue system of this invention is used to monitor lung and immune system exposure of pathogen and / or toxins. The method involves growing engineered lung / immune tissue from progenitor cells in a bioreactor and then exposing the engineered lung / immune tissue to a pathogen and / or toxin. Once exposed, response of the engineered tissue is monitored to determine the effects of exposure to the immune component of the tissue and to lung component of the tissue. This invention also involves development of mixed engineered tissues including a first fully functional engineered tissue such as lung tissue and a second fully functional engineered tissued such as immune tissue from a single animal donor. The mixed systems can include more than two engineered tissues.

The invention provides a SARS-CoV-2 vaccine using human type-5 replication-defective adenovirus as a vector. The vaccine uses E1 and E3 to be combined with replication-defective human type-5 adenovirus as the vector and HEK293 cells integrating adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is the 2019 SARS-CoV-2 S protein gene (Ad5-nCoV) which is subjected to optimization design. After the S protein gene is optimized, the expression level in transfected cells is increased significantly. The vaccine has good immunogenicity in mouse and guinea pig models, andcan induce a body to produce a strong cellular and humoral immune response in a short time. Studies on the protective effect of hACE2 transgenic mice show that after 14 days of single immunization ofAd5-nCoV, the viral load in lung tissue can be significantly reduced, and it is indicated that the vaccine has a good immunoprotective effect on the 2019 SARS-CoV-2. In addition, the vaccine is quick, simple and convenient to prepare, and can be mass-produced in a short period of time to respond to sudden outbreaks.

Methods of delivering an agent in a tissue-specific manner, particularly lung tissue, by targeting a protein expressed on the endothelial cell surface, are described. The methods can be used for detecting, imaging and / or treating pathologies, as well as for diagnostics.

The present invention relates to a new formulation comprising a stabilized GLP-1 compound, such as an analog, fragment or derivative thereof for delivery across pulmonary tissue in vivo.

The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for example, a cross-linkable moiety, an imaging moiety, and / or one or more other targeting moieties. The methods and compositions of the invention find use, for example, in detecting and treating a pulmonary condition such as emphysema.

The present invention comprises an optical apparatus, methods and uses for real-time (video-rate) multimodal imaging, for example, contemporaneous measurement of white light reflectance, native tissue autofluorescence and near infrared images with an endoscope. These principles may be applied to various optical apparati such as microscopes, endoscopes, telescopes, cameras etc. to view or analyze the interaction of light with objects such as planets, plants, rocks, animals, cells, tissue, proteins, DNA, semiconductors, etc. Multi-band spectral images may provide morphological data such as surface structure of lung tissue whereas chemical make-up, sub-structure and other object characteristics may be deduced from spectral signals related to reflectance or light radiated (emitted) from the object such as luminescence or fluorescence, indicating endogenous chemicals or exogenous substances such as dyes employed to enhance visualization, drugs, therapeutics or other agents. Accordingly, one embodiment of the present invention discusses simultaneous white light reflectance and fluorescence imaging. Another embodiment describes the addition of another reflectance imaging modality (in the near-IR spectrum). Input (illumination) spectrum, optical modulation, optical processing, object interaction, output spectrum, detector configurations, synchronization, image processing and display are discussed for various applications.

Elongate implant structures can be introduced into an airway system to a target airway axial region, often to apply lateral bending and / or compression forces against the lung tissue from within the airways for an extended period of time. Structures or features of the implants may inhibit tissue reactions that might otherwise allow portions of the device to eventually traverse through the wall of the airway. The devices may enhance the area bearing laterally on the tissue of a surrounding airway lumen wall. Embodiments may have features which increase the device friction with the airway to allow the device to grip the surrounding airway as the device is deployed. An appropriate adhesive may be introduced around the device in the lung. Hydrophilic material may inhibit biofilm formation, or features which induce some tissue ingrowth (stimulation of tissue growth) may enhance implanted device supported

A pneumostoma management system includes a pneumostoma management device for maintaining the patency of a pneumostoma and a drug delivery device for pneumostoma care. The drug delivery device includes a therapeutic agent dispenser for supplying a therapeutic agent and a propellant at positive pressure, a tube for entering the pneumostoma and a limiting device for limiting the depth of insertion of the tube into a pneumostoma. The drug delivery device may be used to introduce therapeutic agents into the pneumostoma for direct treatment of the pneumostoma, treatment of the lung by way of collateral ventilation, and / or treatment of non-lung tissues by diffusion into the bloodstream.

A pneumostoma management system includes a pneumostoma management device for maintaining the patency of a pneumostoma and a drug delivery device for pneumostoma care. The drug delivery device may be used to introduce therapeutic agents into the pneumostoma for direct treatment of the pneumostoma, treatment of the lung by way of collateral ventilation, and / or treatment of non-lung tissues by diffusion into the bloodstream. The drug delivery device includes a therapeutic agent dispenser for supplying a therapeutic agent and a propellant at positive pressure, an outlet and a connector for correctly positioning the outlet relative to a pneumostoma management device. The drug delivery device includes a self-centering and self-sealing connector for engaging the pneumostoma management device.

The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.

Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 μg / gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.

Provided herein are devices, systems, and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, devices, systems, and methods are provided for delivering energy to difficult to access tissue regions (e.g. central or peripheral lung tissues), and / or reducing the amount of undesired heat given off during energy delivery.

The invention discloses a multifunctional fusion polypeptide and a preparation method and application thereof, and belongs to the field of biological pharmacy. The fusion polypeptide has the structural domains of Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu, Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, Arg-Gly-Asp and Gly-Gly-Gly-Gly; the fusion polypeptide can treat human lung fibrosis, pathological changes of lung tissue, lung cancers and other tumors, and in a lung fibrosis cell model, the fusion polypeptide can significantly reduce the hydroxyproline content in model group cells and inhibit the process of lung fibrosis. It is shown through MTT tests that the fusion polypeptide can inhibit proliferation of multiple kinds of anthropogenic tumor cells; the fusion polypeptide is prepared through an artificial synthesizing method, the preparation method is simple, and a good application prospect is achieved.

Elongate implant structures can be introduced into an airway system to a target airway axial region, often to apply lateral bending and / or compression forces against the lung tissue from within the airways for an extended period of time. Structures or features of the implants may inhibit tissue reactions that might otherwise allow portions of the device to eventually traverse through the wall of the airway. The devices may enhance the area bearing laterally on the tissue of a surrounding airway lumen wall. Embodiments may have features which increase the device friction with the airway to allow the device to grip the surrounding airway as the device is deployed. An appropriate adhesive may be introduced around the device in the lung. Hydrophilic material may inhibit biofilm formation, or features which induce some tissue ingrowth (stimulation of tissue growth) may enhance implanted device supported.

The preparation process of Chinese herbal medicine additive in cigarette includes the following steps: preparing Chinese herbal leached solution, preparing Chinese herbal extractum, preparing tobacco shred enzyme digest, mixing Chinese herbal extractum, reducing sugar and tobacco shred enzyme digest and final reaction in a Maillard reactor at 110-128 deg.c for 15-45 min. The additive has both the aroma of flue-cured tobacco and disease preventing and treating effect, can reduce the harm of cigarette to lung tissue. It is added into tobacco shred and is smoker acceptable.

Relating to the fields of biotechnologies and gene therapy, the invention provides application of a gene modified mesenchymal stem cell in pulmonary fibrosis treatment. The gene modified mesenchymal stem cells are obtained through: in-vitro isolated culture and amplification of a mesenchymal stem cell (MSC) deriving from bone marrow and an umbilical cord, and recombinant adenovirus Ad-HGF mediated in-vitro modification of the MSC by a hepatocyte growth factor (HGF). By transplanting the gene modified MSC to a C57 mouse to intervene in radiation induced lung injury and fibrosis, exudation of a plurality proteins including albumin, IgM and the like from an alveolar space can be reduced, local inflammatory responses of the lung can be alleviated, and expression of TNF-alpha, soluble ICAM-1 and multiple factors is inhibited, expression of the profibrotic factor TGF-beta, the collagen gene col1 alpha 1 and col 3 alpha 1 can be inhibited, and pulmonary tissue collagen fiber deposition is reduced. The expression results of endogenous HGF and its receptor cmet show that endogenous HGF expression can be induced and endogenous MSC can home to injured parts. Therefore, the employment of HGF modified MSC in treatment of lung injury and fibrosis brought by various pathogenic causes is of great significance.

The invention relates to a health product, in particular to a soft capsule and a method for producing the same. The soft capsule is characterized in that: the soft capsule contains water soluble pearl powder, selenium-enriched yeast, natural vitamin E, beeswax, glycerol monostearate, span-80 and corn oil. The soft capsule is a powerful antioxidant which can effectively improve the rancidity of fatty acid in food and the alimentary tract, and protect cells from being damaged by harmful matters generated by oxidation of unsaturated fatty acid; the soft capsule is an extremely good free radical scavenger which can protect biological membranes from being attacked by free radicals, effectively resist ageing nutrients, improve immunity of a human body, keep the integrity of red blood cells and promote the biological synthesis of the red blood cells; the soft capsule is an indispensible promoting factor for cellular respiration, which can protect the lung tissue from air pollution; moreover, the soft capsule also can prevent the over-aggregation of blood platelets, avoid the increase of lipid peroxidation in the blood, prevent cardiovascular diseases and supplementing calcium element in the human body.

The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, antiallergic and anti-asthmatic activity. The extractof Pseudolysimachion genus plantand the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL- 13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting definitive endoderm formation from pluripotent stem cells. The invention disclosed herein further relates to methods and systems for promoting ventral-anterior foregut spheroid tissue formation, 3-dimensional lung tissue formation, and lung organoid tissue formation produced in vitro from the described methods

Method and system that provides, among other things, the capability for using hyperpolarized xenon-129 as a probe to non-invasively and non-destructively characterize important properties of certain structures or materials into which hyperpolarized xenon-129 can be introduced and wherein the xenon exists in two or more chemically-shifted states that are in exchange High-resolution MR images can be generated in a fraction of a second wherein the associated signal intensities reflect material properties that characterize the gas exchange among the different states. For example, in the human or animal lung, the system and related method can exploit the differences in gas-exchange characteristics between healthy and diseased lung tissue to generate high-resolution, high signal-to-noise cross-sectional MR images that permit non-invasive regional detection of variations in lung tissue structure with a combination of spatial and temporal resolution that is unmatched by any current imaging modality.

The invention discloses application of kaempferol in preparation of medicines for preventing and treating radiation-induced pulmonary injury. The experiment proves that kaempferol can obviously improve inflammatory exudation of lung tissues suffering from the mouse radiation-induced pulmonary injury and has an excellent positive effect on the radiation-induced pulmonary injury. The invention provides a novel drug for radiation-induced pulmonary injury diseases. A novel thought is provided for research and development of medicines for treating the radiation-induced pulmonary injury, and the application path of kaempferol in the field of medicines is widened.

The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells.

The invention belongs to the fields of cell biology and tumor tissue engineering materials and provides a three-dimensional tumor model decellularization porous scaffold, a construction method and application thereof. The whole pig lung scaffold is prefrozen, a uniform part without obvious bronchi is selected and sliced, purified water and PBS are added for cleaning until no blood streak is formed, removing cells with sodium dodecyl sulfate and TritonX-100, and freezing, drying and chemical crosslinking methods are adopted, so that a crosslinked decellularization pig lung three-dimensional tumor model scaffold is obtained. The three-dimensional tumor model decellularization porous scaffold provided by the invention has the advantages that decellularization matrix sourced from pig lung tissues is taken as a scaffold material for constructing a tumor model, on the basis of effectively removing cell components, a pulmonary alveolus-bronchus structural vein network is reserved as soon as possible, a natural extracellular matrix microenvironment can be simulated, and cell adhesion, growth and proliferation are facilitated. The in vitro constructed three-dimensional tumor model after cells are inoculated has a tissue structure closer to an in vivo tissue and is applicable to screening study of anticancer drugs.

A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.

Provided are methods of treating lung cancer in a patient in need thereof. The method includes administration to the patient a composition comprising a therapeutically effective amount of a compound that reduces the expression level of E3 ubiquitin-protein ligase MDM2. The compound in certain instances is a miR-660 miRNA, or a functional variant thereof. The patient in need of treatment in certain instances expresses miR-660 in a lung tissue sample or biological fluid sample at a level lower as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof, that have been given a favorable prognosis; expresses MDM2 at a higher level in a lung tissue sample or biological fluid sample as compared to a control level derived from a subject or plurality of subjects that do not have lung cancer, or as compared to a control level derived from a lung cancer patient or plurality thereof that have been given a favorable prognosis; and / or expresses p53 in a lung tissue sample or a biological fluid sample below a control level derived from a lung tumor tissue sample, or plurality thereof, or a biological fluid sample, or plurality thereof, obtained from a patient that has a favorable lung cancer prognosis; or a control level derived from a healthy subject.